Posted by Michael Wonder on 26 Jul 2025
Health Canada grants marketing authorisation for Bayer’s Lynkuet (elinzanetant)
25 July 2025 - Authorisation is supported by data from the Phase 3 OASIS clinical trial program evaluating Lynkuet for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes or night sweats) associated with menopause.
Bayer announced today that Health Canada has issued a Notice of Compliance for Lynkuet (elinzanetant capsules) for the treatment of moderate to severe vasomotor symptoms (also known as hot flashes or night sweats) associated with menopause.
